The pivotal phase 3 clinical trial is the first of 2 that will evaluate the use of DURAVYU for the treatment of wet age-related macular degeneration.

Kriya Therapeutics presented preclinical data on its gene therapy candidate for the treatment of geographic atrophy.

Ophthalmologist Tarek Hassan introduces new surgical approach for proliferative vitreoretinopathy, using precise small retinotomies instead of extensive retinal removal to improve patient outcomes.

Biotechnology company Lineage Cell Therapeutics recently announced it will be presenting data from its phase 1/2a clinical study (NCT02286089) at the upcoming Clinical Trials at the Summit (CTS) 2025 ...

Sylentis recently announced topline results from the SYL1801_II phase 2a study investigating SYL1801 for the treatment of ...

Ashvattha Therapeutics recently announced positive interim phase 2 results for migaldendranib (MGB). 1 MGB is described as a novel subcutaneously administered nanomedicine for the treatment of retinal ...

Four-year study shows faricimab in treat-and-extend regimen maintains vision for diabetic macular edema patients with significantly fewer injections over time. Matt Star, MD, assistant professor of ...

Ultra-wide field imaging shows nonperfusion and leakage independently predict diabetic retinopathy progression, suggesting earlier treatment with anti-VEGF or photocoagulation may prevent ...

Post hoc analysis of GATHER1 and GATHER2 showed that reduced EZ-RPE central subfield thickness is a strong predictor of greater future vision loss. A post hoc analysis of the GATHER1 and GATHER2 ...